HomeStartups Teva Pharmaceuticals lifecycle

Claimed by owner Last Update Jun 3, 2026 Suggest Edits Claim Profile

Claimed by owner

Teva Pharmaceuticals

Generic and Specialty Pharmaceuticals

PUBLIC on TASE on Jan 1951

PUBLIC on NYSE on Jan 1982

Teva Pharmaceuticals

Teva Pharmaceuticals Overview

Cumulative Funding Raised Over Time ($)

Employees Over Time

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

Teva to Present at the Goldman Sachs Global Healthcare Conference

Is Veeva (VEEV) Quietly Redefining Its Moat With Deeper AI-Driven Life Sciences Integration?

Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks

A Look At Teva (TEVA) Valuation After New Real World Tardive Dyskinesia Data Release

J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?

Teva Pharmaceuticals Commits to Veeva Vault CRM

Interact Enters a New Era of Growth with Brand Evolution, AI Innovation, and Industry Recognition

TEVA's MAA for Olanzapine LAI in Schizophrenia Accepted in the EU

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

Teva TD Findings Highlight Underdiagnosis And Shape Neuroscience Growth Story

Polymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

Teva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx Deal

Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More.

Is It Too Late To Consider Teva Pharmaceutical Industries (TEVA) After Its 3‑Year Rally?

Former Ovid CEO Dr. Jeremy Levin’s rallying cry for biotech

Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right.

Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End

Deckers Brands Announces Conference Call to Review Fourth Quarter and Full Fiscal Year 2026 Earnings Results

Alvotech Q1 Earnings Call Highlights

Solid Earnings Reflect Teva Pharmaceutical Industries' (NYSE:TEVA) Strength As A Business

Teva Pharmaceutical Industries Q1 Earnings: AUSTEDO Surges as Teva Plots $700M Emalex Buyout

How The Investment Story For Teva Pharmaceutical Industries (TEVA) Is Shifting With New Analyst Focus

Teva to Present at the BofA Securities Health Care Conference

Is Deckers Outdoor Corporation (DECK) A Good Stock To Buy Now?

Is Teva Pharmaceutical Industries Limited (TEVA) A Good Stock To Buy Now?

Teva (TEVA) Enters a New $700 Million Acquisition Deal

Teva Pharmaceutical Industries Q1 Earnings Call Highlights

A Look At Teva (NYSE:TEVA) Valuation After Robust First Quarter 2026 Earnings Reaction

Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?

Teva signs off $900m Emalex buyout amid strategic pipeline boosting ploy

Analysis of the 2026 Oral Solid Dosage Contract Manufacturing Market - Scalable Pharma Solutions & Generic Demand Drive $59.05 Billion Forecast for 2030

Teva Pharmaceuticals (TEVA) Soars 12% as Profits Hit New Record

TEVA Q1 Earnings Top Estimates, Branded Drugs Drive Revenues, Stock Up

Teva Pharmaceutical Industries Ltd (TEVA) Q1 2026 Earnings Call Highlights: Strong Innovative ...

Teva Pharmaceutical Industries Positioned for Re-Rating on Growth Drivers, UBS Says

Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy

Teva nabs experimental Tourette drug in $700M Emalex buyout

Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say

The move strengthens Teva's pipeline with Tourette’s treatment and supports its “Beyond Growth” strategy.

The Israeli pharmaceutical company has also announced first quarter results, which beat the analysts’ predictions.

Teva Surges As Its New Growth Strategy Hits A Key Inflection Point

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Teva Pharmaceutical (TEVA): David Einhorn Likes This Pharma Stock

AMRX Valuation: What 1.69x Sales Means for Investors

AMRX Growth Drivers: Generics, Biosimilars, and Crexont

Dermal Mycosis Market Research Report 2025-2026 & 2035, Competitive Analysis of Bayer, Kenvue, Karo Healthcare, Novartis, Glenmark Pharmaceuticals, Sun Pharma, Teva, and Sandoz

Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock.

Teva beats estimates but cuts profit outlook after Emalex deal | Ctech

What to Expect From Deckers Outdoor's Q4 2026 Earnings Report

Is It Too Late To Consider Teva (TEVA) After Its 118% One Year Share Price Surge?

Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - Kaken Pharma, Novartis, Glenmark Pharma, Sun Pharma, Teva Pharmaceutical, Bayer, and Galderma

How to Play J&J Stock Post a Beat-and-Raise Performance in Q1

Novo’s Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%.

Teva Pharmaceutical Industries Limited (TEVA): David Einhorn Trims Holding

3 Catalysts That Could Send Teva Stock to $40 and Beyond

Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors

How Teva Pharmaceutical Industries (TEVA) Story Is Shifting With Duvakitug R&D And Biosimilars

J&J Targets Double-Digit Growth by 2030 Despite Stelara Drag

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

J&J Beats Q1 Earnings & Sales Estimates, Raises 2026 Outlook

BofA Raises its Price Target on Teva Pharmaceutical (TEVA) to $42

How The Corcept Therapeutics (CORT) Investment Story Is Shifting After Legal And Regulatory Updates

Is AMRX Stock Undervalued? Sales Multiple, Target, Upside

AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook

Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing

Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?

Israeli Stocks Rise as Investors Weigh Up Fragile Iran Truce

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

Teva Pharmaceutical Industries Limited (TEVA): Billionaire Stan Druckenmiller Trims Position

Teva Pharmaceutical: Among the 13 Cheapest Strong Buy Stocks to Buy Right Now

Factors Supporting Teva Pharmaceutical’s (TEVA) Long-Term Profitability

PONLIMSI Biosimilar Approval and Xolair Filings Could Be A Game Changer For Teva Pharmaceutical Industries (TEVA)

TEVA's Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted

Teva receives FDA approval for Prolia biosimilar

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

Blackstone closes largest ever private funding investment round at $6.3bn

Immunic appoints biopharmaceutical executive Jon Congleton to board

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After A Sharp One Month Share Price Pullback

Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)

J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?

Teva Releases Q1 2026 Aide Memoire

Alvotech Q4 Earnings Call Highlights

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

A Look At Teva Pharmaceutical Industries (TEVA) Valuation After Recent Share Price Pullback

Is It Too Late To Reassess Teva Pharmaceutical Industries (TEVA) After Its 75% One Year Rally?

Is Teva Pharmaceutical Industries (TEVA) A Good Stock To Buy Now?

Does Blackstone’s Private Credit Strains And AI Push With Anthropic Reshape The Bull Case For BX?

Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics

Blackstone (BX) Commits $400 Million With Teva to Advance Duvakitug Clinical Development

Is Deckers Outdoor Stock Underperforming the Nasdaq?

Compugen Ltd. (CGEN) Reports Q4 Revenue of $67.3 Million vs. $1.5 Million Last Year

Assessing Deckers Outdoor’s (DECK) Valuation After Recent Analyst Upgrades And Earnings Optimism

Richard Francis sells stock after Teva’s 110% rally over the past year.

The 3 Best Stocks to Invest $1,000 in Right Now

Teva And Blackstone Deal Highlights Shift Toward Higher Value Drug Pipeline

#Product Stage #Partners #Investment

Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead?

#Product Stage #FDA approved/pending approval

Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's

Forget Teva: This Dividend Top Dog Is the Real Value Buy Today

3 Generic Drug Stocks to Watch Despite Industry Headwinds

Blackstone puts $400M into Teva, Sanofi gut disease drug

The funding bolsters late-stage development of Duvakitug as the company races toward a $30 billion market.

#Product Stage #Partners #Investment

7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036

#Product Stage #FDA approved/pending approval

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

#Investment #Partners #Product Stage

The Best Healthcare Stock to Invest $1,000 in Right Now

#Product Stage #Customers #Partners

How Positive Duvakitug IBD Data and New Schizophrenia Drug Filing Will Impact Teva (TEVA) Investors

#Product Stage #FDA approved/pending approval

Glenview Capital Management Opens New $96 Million Position in DigitalOcean

#Investment

J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?

#Acquisition #Product Stage

Where is Teva Pharmaceutical Industries Limited (TEVA) Headed?

#Product Stage #Partners

Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole

Teva And Sanofi Data Add Potential Branded Growth Option In IBD

#Product Stage #Partners

מנהל המזון והתרופות בארה"ב הודיע שמעכשיו חברות יידרשו לבצע ניסוי יעילות גדול אחד במקום שניים, כפי שהיה נהוג עד כה ● מדובר בשינוי שיאפשר להוזיל ולקצר משמעותית את הפיתוח ● בתעשייה מרוצים, אבל לד"ר ג'רמי לוין, מנכ"ל טבע לשעבר, יש גם אזהרה לישראלים

#Product Stage #FDA approved/pending approval

Corcept's Q4 Earnings and Revenues Fall Short of Estimates

#Product Stage #FDA approved/pending approval

Corcept Therapeutics Q4 Earnings Call Highlights

#Product Stage #Customers #FDA approved/pending approval

Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?

Teva to Present at the Upcoming Investor Conferences in March

Are Wall Street Analysts Bullish on Deckers Outdoor Stock?

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong Recent Share Price Momentum

#Product Stage

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

#Product Stage #Partners

Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities

#Product Stage #FDA approved/pending approval

Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

#Product Stage #Partners

Teva Pharmaceutical Industries (TEVA) Upgraded to Buy: Here's What You Should Know

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

What Analysts Think Gives Teva Pharmaceutical Industries NYSE TEVA A Changing Story Into 2026

#Product Stage

Goldman Sachs See Teva Pharmaceutical Industries Limited (TEVA) Driving Double-Digit Earnings Growth Through 2026

FDA accepts BMS protein degrader for review; Disc rare disease drug rejected

#FDA approved/pending approval

$198.39 Bn Active Pharmaceutical Ingredients (API) Markets, 2030 by Synthesis (synthetic, Biotech), Potency (HPAPI), Product (mAbs, Hormones), Drug (OTC, Rx), Application (Diabetes, Oncology)

Should You Invest in Teva Pharmaceutical (TEVA), Here’s What the Street Has to Say

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

#Product Stage

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is largely controlled by institutional shareholders who own 74% of the company

Teva Pharmaceutical Industries' (NYSE:TEVA) Solid Earnings Are Supported By Other Strong Factors

Here’s What Analysts Are Saying About Teva Pharmaceutical (TEVA) Post Earnings

How Good Is Teva Pharmaceutical Industries Limited (NYSE:TEVA), When It Comes To ROE?

Is Teva Pharmaceutical Industries Limited (TEVA) an Undervalued Stock Relative to Its Long-Term Potential?

#Partners

How The Shifting 2026 Pipeline Story Is Reshaping Teva Pharmaceutical Industries’ Valuation

Deckers Outdoor Corporation (DECK): A Bull Case Theory

#Management Changes #Expand

Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat

#Product Stage #FDA approved/pending approval

Alvotech (ALVO): A Bull Case Theory

#Partners #Customers

Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

#Product Stage

Evaluating Teva Pharmaceutical Industries (TEVA) After Earnings Beat And Return To Profitability

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

#Product Stage #Customers

The Druckenmiller Connection: Meet the Man Behind Bessent and Warsh

Teva Canada Announces Strategic Partnership with Novartis Canada to Relaunch Mayzent® for Multiple Sclerosis Patients in Canada

#Partners

Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)’s 2026 Growth Despite Revenue Headwinds

#Product Stage #Customers

This Stock Is Up Nearly 10,000% Since Its IPO And It Just Stunned Wall Street. Why It Could Go Even Higher.

#Customers

Jim Cramer Highlights Teva Pharmaceutical’s Growth Under CEO Richard Francis

#Management Changes

Does Teva’s Return To Profitability And Branded-Drug Shift Reshape The Bull Case For TEVA?

#Product Stage #Investment

TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth

#Product Stage #Partners #Customers

Teva Pharmaceutical Industries Q4 Earnings Call Highlights

#Product Stage #Customers #Partners #Investment

Innovative drugs surge, but 2026 forecasts revive investor doubts.

#Product Stage #Layoffs #Partners #FDA approved/pending approval

Is Teva (TEVA) Still Offering Value After A 79% One Year Share Price Surge

Novo Nordisk Faces Class Action Over Victoza Generic Delay

What Makes Teva Pharmaceuticals (TEVA) a Successful Brand?

#Customers

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

#Product Stage #Investment

Teva Pharmaceutical Industries (NYSE:TEVA) shareholder returns have been strong, earning 209% in 3 years

Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?

#Acquisition #Investment

Teva Pharma Slides On Light 2026 Outlook Despite Fourth-Quarter Beat

After three consecutive years of growth, the Israeli pharmaceutical company predicts a small decline this year.

Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock

Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)

#Partners #Product Stage

Teva (TEVA) Q3 2025 Earnings Call Transcript

#Product Stage #Customers #Partners #Management Changes

Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say

J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both Units

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

#Partners

Jim Cramer on Royalty Pharma: “It’s a Terrific Company”

#Partners #Product Stage

Is There An Opportunity With Teva Pharmaceutical Industries Limited's (NYSE:TEVA) 45% Undervaluation?

What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q4 Earnings

J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales

Deckers Brands Announces Conference Call to Review Third Quarter Fiscal 2026 Earnings Results

Assessing Teva Pharmaceutical Industries (TEVA) Valuation After Recent Share Price Momentum

Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?

JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency

#Product Stage #Customers #Investment

ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now?

#Product Stage #Acquisition

Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy?

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

#Product Stage

Is It Too Late To Reassess Teva (TEVA) After A 55% One Year Rally?

Teva's Plans to Pivot to Growth

Agreement with Royalty Pharma underscores shift toward branded medicines.

#Product Stage #Partners #Investment #Layoffs

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

Teva Stock Is Jumping. Why Investors Are So Optimistic on the Drugmaker.

Royalty Pharma will provide up to $500 million for development of a treatment for vitiligo.

#Partners #Investment #Product Stage

Prof. Michael Hayden left Teva taking two products that it had begun developing. One became an almost $3.5 billion exit last September.

#Acquired-by

TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug

#Product Stage #Partners #Investment

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

#Investment #Partners #Product Stage

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

#Product Stage #Partners #Investment

Teva Pharmaceutical Industries Limited's (NYSE:TEVA) high institutional ownership speaks for itself as stock continues to impress, up 3.4% over last week

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32

How Investors Are Reacting To Teva (TEVA) Earnings Beat And New Schizophrenia And Osteoporosis Drugs

#Product Stage #FDA approved/pending approval

How Recent Guidance And Price Targets Are Reframing The Story For Teva Pharmaceutical Industries (NYSE:TEVA)

#Product Stage #Investment #FDA approved/pending approval #Partners

ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now?

#Acquisition #Product Stage

Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings?

#Acquired-by

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Momentum

Should You Buy the Dip in This S&P 500 Underdog in 2026?

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)?

Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

#Management Changes

Here's What to Expect From Deckers Outdoor's Next Earnings Report

This International Pharma Stock Just Hit 5-Year Highs

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play

Teva Pharmaceutical Industries' (NYSE:TEVA) investors will be pleased with their impressive 228% return over the last three years

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

#Product Stage #Partners #FDA approved/pending approval

Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock

Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program

#Product Stage #Partners

BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight

#Product Stage #FDA approved/pending approval

S&P 500 Stocks: These 2 Lagging Retailers Become Leaders In December

3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today

FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock?

#Product Stage #Partners

Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?

Has Teva’s 80% Surge in 2024 Already Priced In Its Turnaround Potential?

#Partners

Will Teva’s (TEVA) Extended Sustainability-Linked Credit Line Reshape Its Balance Sheet and Risk Narrative?

#Investment

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

Teva Releases Q4 2025 Aide Memoire

Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks

#Investment

TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia

#Product Stage #FDA approved/pending approval

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's

Looking at the Narrative for Teva After Evolving Price Targets and Austedo Outlook

#Product Stage #Customers #Partners #FDA approved/pending approval

Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing

#Investment

Teva Pharmaceutical Industries (NYSE:TEVA): Reassessing Valuation After a Strong Multi‑Month Share Price Rebound

Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application1 Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults

#Product Stage #Partners #FDA approved/pending approval

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

#Product Stage

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

#Product Stage #Customers

Is Deckers Outdoor Stock Underperforming the S&P 500?

Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?

#Product Stage #Customers

3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape

#Product Stage #Investment

Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue

Can Galafold Continue to Drive Amicus' Top Line in 2026?

#Product Stage #Partners

Should We Be Cautious About Teva Pharmaceutical Industries Limited's (NYSE:TEVA) ROE Of 9.1%?

Israel Has Been Mired In Controversy During Its War With Hamas. Big Tech Investment Tells A Different Story.

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America

#Management Changes

With 72% ownership in Teva Pharmaceutical Industries Limited (NYSE:TEVA), institutional investors have a lot riding on the business

European Biosimilar Approvals Could Be a Game Changer for Teva Pharmaceutical Industries (TEVA)

#Product Stage #Customers

Is Teva a Bargain After 27% Surge and Cost-Cutting Headlines?

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied

What Are Wall Street Analysts' Target Price for Deckers Outdoor Stock?

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

#Product Stage #Customers

Why Analysts See Teva’s Story Shifting With New Approvals and Rising Price Targets

This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now.

#Investment

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

#Product Stage #Partners

Teva (NYSE:TEVA): Exploring Valuation After a 29% One-Month Rally

Teva seeks startups to help solve global pharmaceutical challenges

#Partners

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion

ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?

#Acquisition #Product Stage

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

We Like The Quality Of Teva Pharmaceutical Industries' (NYSE:TEVA) Earnings

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

How Recent Developments Are Rewriting the Story for Teva Pharmaceutical Industries

#Product Stage #Customers #Partners #FDA approved/pending approval

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

#Product Stage

Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?

The pharmaceutical company recorded its 11th consecutive quarter of growth, with revenue of $4.5 billion, thanks to sales of its brand-name drugs Austedo, Ajovy and Uzedy, which jumped 33%.

#Layoffs #Customers #Partners #FDA approved/pending approval

S&P 500 Futures Dip as Rate and Debt Worries Mount

#Partners

Teva Canada Welcomes RAMQ Reimbursement Update Supporting Access to ADHD Treatments

TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up

Teva (TEVA) Hits All-Time High as Q3 Strengthens FY25 Profitability Expectations

Sector Update: Health Care Stocks Advance Late Afternoon

Despite concerns, the forecast for sales of branded drug Austedo remain unchanged even though the US Inflation Reduction Act (IRA) aims to cut pharmaceutical prices.

Sector Update: Health Care Stocks Higher in Afternoon Trading

Apple's reported Google deal, Teva & Axon post-earnings moves

#Acquisition

Top Midday Stories: McDonald's Shares Rise After Q3 Same-Store Sales Growth; AMD Q3 Adjusted EPS, Revenue Beat Estimates

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

#Product Stage #Customers #FDA approved/pending approval

Medincell: UZEDY® Continues Strong Growth; Teva Setting the Stage for US NDA Submission for Olanzapine LAI in Q4 2025

#Product Stage #Partners #FDA approved/pending approval

Why Teva Pharmaceutical Stock Rocked the Market Today

Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries (TEVA) Q3 Earnings

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2025 Earnings Call Highlights: Strong Growth ...

#Product Stage #Customers #Partners

Revenue climbs 3% to $4.5 billion, exceeding analysts’ expectations.

#Layoffs

Teva Hits Highest Since 2018 as 3Q Revenue Beats Estimates

Teva Pharma Surges On Its Big Sales Beat, Austedo Guidance Hike

#Customers

Did Phoenix Financial's Big Stake Boost Just Shift Teva (TEVA) Pharmaceuticals' Turnaround Narrative?

#Investment

Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

Since the stock’s low-point in 2025 in April, the Israeli pharmaceutical company’s share price has risen over 60%.

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

LEO Pharma Strengthens Leadership in Medical Dermatology with the Appointment of Sophie Lamle as Chief Development Officer

#Management Changes

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

Net zero tax ‘will drive up NHS medicine prices’

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation: Is There Untapped Value After Recent Uptrend?

Trump Administration Eases Approval Process for Biosimilar Drugs

Teva Pharmaceutical (TEVA) Enters Into a License Agreement With Prestige Biopharma for the Commercialization of Tuznue in Europe

#Partners

Deckers Brands Reports Second Quarter Fiscal Year 2026 Financial Results

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

#Product Stage #Investment

UBS Maintains Bullish Outlook on Deckers Outdoor Corporation (DECK) as Analysts Monitor HOKA’s U.S. Growth Recovery

Teva (TEVA) Gains FDA Approval for UZEDY Injectable in Bipolar I Disorder Treatment – What's Changed

#FDA approved/pending approval

JPMorgan and UBS Raise PT for Teva Pharmaceutical (TEVA)

Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar

Bank of America Securities Raises PT on Teva Pharmaceutical Industries (TEVA), Keeps a Buy

Johnson & Johnson Targets Accelerated Growth Across Segments in 2026

Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?

Does Teva Pharmaceutical Industries (TEVA) Have the Potential to Rally 28.12% as Wall Street Analysts Expect?

All You Need to Know About Teva Pharmaceutical Industries (TEVA) Rating Upgrade to Buy

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

#Partners

What Recent Earnings Reveal About Teva’s Valuation in 2025

Teva Pharmaceutical Receives FDA Approval to Expand UZEDY Indication for Maintenance Treatment of Bipolar I Disorder

#FDA approved/pending approval

Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock

JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit

Deckers Brands Announces Conference Call to Review Second Quarter Fiscal 2026 Earnings Results

TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder

#Product Stage #Partners

BofA Raises Teva Pharmaceutical (TEVA) PT to $24, Amid “Pivot to Growth” Strategy Execution

Evaluating Teva (NYSE:TEVA) Valuation After FDA Expands UZEDY Approval to Bipolar I Disorder

#Product Stage #FDA approved/pending approval

Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

#FDA approved/pending approval #Partners

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Medincell: FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

#FDA approved/pending approval

SoftBank, HSBC, Teva, Ferrari: Stocks Worldwide in Focus

#Acquisition

Overcoming past mistakes, generics powerhouse Teva embraces an innovative ‘mindset change’

#Product Stage #Partners

Teva (TEVA) Is Up 9.2% After New Schizophrenia Drug Data and Innovation Shift - What’s Changed

#Product Stage #FDA approved/pending approval

Truist Securities Reaffirms Its Buy Rating for Teva Pharmaceutical Industries Limited (TEVA)

#Product Stage #Expand

UBS Maintains its Buy Rating on Teva Pharmaceutical Industries Limited (TEVA); Raises Its Price Target to $26.00

Can Galafold Drive Amicus' Growth Through the Rest of 2025?

#Product Stage #Partners

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

Here's How Alvotech is Expanding its Portfolio Beyond Immunology

#Partners #Customers #Product Stage

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Teva Releases Q3 2025 Aide Memoire

Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?

#Partners #Customers #Product Stage

Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®

#Product Stage #Partners

J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?

#Product Stage #Acquisition #FDA approved/pending approval

Medincell: New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®

#Product Stage #Partners #FDA approved/pending approval

Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed

#Product Stage #Partners

Teva Pharmaceutical Industries (NYSE:TEVA): Evaluating Valuation Potential After Recent Share Movement

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

#Product Stage

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Roche strikes $3.5 billion deal for U.S.-Israeli biotech 89bio | CTech

#Acquired-by

Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth

#Partners #Customers #Product Stage

J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why

#Product Stage #Customers

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

#Product Stage #Partners

How Is Deckers Outdoor Corporation's Stock Performance Compared to Other Consumer Discretionary Stocks?

Teva Pharmaceutical Industries (TEVA) Attains FDA’s Fast Track Designation for Emrusolmin

#Product Stage #Partners

Teva Pharmaceutical Industries Limited (TEVA)’s Emrusolmin Gains FDA Fast Track for Multiple System Atrophy

#Product Stage #FDA approved/pending approval

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

#Product Stage

J.P. Morgan Maintains a Buy on Teva Pharmaceutical (TEVA) With a $23 PT

#FDA approved/pending approval

Here’s Why Sound Shore Fund Added Teva Pharmaceutical Industries Limited (TEVA) in Q2

#Investment

Assessing the Valuation of Yue Yuen Industrial (SEHK:551) After Recent Volatility

Nifty clocks fifth session of gains led by IT on Infosys buyback, US rate cut hopes

BHP Xplor Opens Applications for 2026 Cohort, Offering Equity-Free Funding and Global Support

#Partners

Westin Desaru Coast Resort partners with CAYIN Technology for digital signage

#Partners

Is Now the Right Moment to Reassess PCCW Amid Strong 2025 Gains?

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

#Product Stage #Partners

Strauss Group (TASE:STRS): Assessing Valuation After Mixed Q2 Earnings and Sales Growth

Does the Recent 24% Drop Signal an Opportunity in NICE for 2025?

Nikkiso Addresses Growing Ammonia-Handling Demand and Launches Next-Generation Pump at Gastech 2025

#Product Stage

Is There Room for Growth in MMG After Its 29.5% Price Surge?

Teva (NYSE:TEVA) Valuation in Focus After FDA Approval and U.S. Launch of Generic Saxenda

#FDA approved/pending approval #Product Stage #Customers

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

#Product Stage #Partners

Anti-Parkinson's Drugs Global Market Research Report 2025-2030 | $9.2 Bn Opportunities Driven by Increased Awareness in Emerging Countries and a Robust Pipeline of Innovations

#FDA approved/pending approval #Product Stage

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Teva Pharmaceutical Industries (TEVA) Announces the FDA Approval and U.S. Launch of Generic Saxenda

#FDA approved/pending approval

Did FDA Approval of Generic Saxenda Just Shift Teva's (TEVA) Investment Narrative?

#Product Stage #FDA approved/pending approval

Teva Pharmaceutical Industries Limited (TEVA) Gains FDA Nod for Pediatric Migraine Drug AJOVY

#Product Stage #FDA approved/pending approval

Teva brings first generic GLP-1 to US market with Saxenda copycat approval

#FDA approved/pending approval

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

#Product Stage #FDA approved/pending approval

Deckers Outdoor Stock: Is Wall Street Bullish or Bearish?

Deckers Outdoor (DECK) Sees 12% Rise in Share Price Over Past Week

#Product Stage #Partners

FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk

#FDA approved/pending approval

J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?

Piper Sandler Reiterates a Buy Rating on Teva Pharmaceutical Industries (TEVA)

Deckers Outdoor (DECK): Assessing Valuation After New Teva Launches and Continued Earnings Momentum

#Product Stage #Customers

Will Teva’s Designer Collaboration and New Collection Signal a Brand Evolution for Deckers (DECK)?

#Product Stage #Customers

CalPrivate Bank Appoints Angel Martinez to the CalPrivate Bank Board

#Management Changes

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Latest Fed cut signals, pharma relief rally, Apple TV+ price hike

Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?

#Customers #Product Stage

US-EU trade deal impacts on pharma industry more 'manageable' than expected

Teva Debuts Autumn Winter 2025 Collection Inspired By "For Playground Earth"

#Product Stage

Teva® and Sean Wotherspoon Reimagine Archival Icons, Bridging Street Style and Outdoor Adventure

#Partners

Deckers Outdoor (DECK) Launches Teva x Sean Wotherspoon Collection Globally

#Partners #Customers

PureTech forms respiratory spin-off Celea to advance deuterated pirfenidone

#Product Stage #Management Changes

Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB

PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases

#Product Stage #Management Changes

Following a 4.2% decline over last year, recent gains may please Teva Pharmaceutical Industries Limited (NYSE:TEVA) institutional owners

Vantage Drilling International Ltd. Announces Completion of the Sale of the Tungsten Explorer

#Partners #Acquisition

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

#Product Stage #Investment

Teva’s Ajovy becomes first migraine prevention drug approved for children

#FDA approved/pending approval

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

#FDA approved/pending approval

Endocarditis Market Global and Regional Research Report 2025-2035 | AI and Molecular Diagnostics Set to Revolutionize Endocarditis Management

According to "The Wall Street Journal," the average target price of 11 investment institutions covering Teva's stock is $24.29, a 57.9% premium on the current share price.

#Layoffs #Product Stage #Customers

TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales

#Product Stage #Partners #Customers

Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA

#Product Stage

Teva CEO on Tariffs, Generic Drugs Market, MFN Pricing

Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings

UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025

#Product Stage #Partners #FDA approved/pending approval

The Israeli pharmaceutical company beat the analysts on profit but missed on revenue in the second quarter of 2025.

#Layoffs

Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy

#Product Stage #Customers

Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect

#Product Stage #Partners #FDA approved/pending approval

Austedo disappoints, while Uzedy and Ajovy drive upside in brand-name drugs.

#Layoffs #Customers

Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics

This is the Most Dangerous Week for Investors in 20 Years

S&P 500 Gains and Losses Today: Deckers Stock Jumps as Global Footprint Grows; Intel Shares Sink

#Layoffs

Deckers Brands Reports First Quarter Fiscal Year 2026 Financial Results

Menora Mivtachim and Phoenix have become parties in interest in the Israeli pharmaceutical company.

#Investment #Layoffs

Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?

EdgeOne Medical Announces Appointment of Michael Denzer as VP, Client Relations to Further Elevate Product Innovation and Client Partnerships

#Management Changes

Trump Aims Tariff Double Whammy at Industries, Nations by Aug. 1

JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise

Deckers Brands Announces Conference Call to Review First Quarter Fiscal 2026 Earnings Results

Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim’s Buy List

TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?

#Product Stage #Partners #Customers

Teva Pharmaceutical (TEVA) Just Flashed a Statistically Viable Signal for Bullish Traders

Teva Partners with Fosun Pharma to Advance Novel Cancer Immunotherapy TEV-56278

#Product Stage #Partners

Teva’s Ajovy Shows Sustained Long-Term Efficacy in Migraine Prevention Trial

#Product Stage

Deckers Outdoor Corporation's Quarterly Earnings Preview: What You Need to Know

Teva Recognized Among TIME and Statista's 2025 World's Most Sustainable Companies

Jim Cramer on Deckers: “I’m Not Ready to Throw in the Towel”

Investors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen solid returns of 112% over the past three years

Teva Releases Q2 2025 Aide Memoire

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

#Product Stage #Partners

Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?

#Investment

Teva reports final analysis of migraine prevention trial of Ajovy

#Product Stage

Goldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth

J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?

#Product Stage #Acquired-by

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy

#Partners

Generic Drugmakers Resist Trump’s Calls for More U.S. Manufacturing

Teva to collaborate with Fosun Pharma for TEV-56278

#Partners #Product Stage

Teva, Fosun Pharma partner to develop TEV-56278

#Partners

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

#Partners #Product Stage

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

#Investment #Customers

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris

3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

CrowdStrike and McDonald’s downgraded: Wall Street’s top analyst calls

Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and Am

#Product Stage #Investment

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

Teva Pharmaceutical Industries Raises Pool Tender Offer, Reports Early Tender Results

#PIPE/PO

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

#Product Stage #Customers

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target

#Layoffs

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

#Product Stage #Customers

Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408

#Product Stage

Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead

#Customers

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

#Product Stage #Partners

Why Is Teva Stock Trading Higher On Tuesday?

#Product Stage #Partners #FDA approved/pending approval

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

#Product Stage

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

#Partners #Product Stage

TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?

#Customers

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

Regulatory Shake-Up Led to the Sell Off in Teva Pharmaceutical Industries Limited (TEVA)

#Management Changes #Product Stage

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

#PIPE/PO

Teva Pharmaceutical Industries (NYSE:TEVA) Upsizes Senior Notes Offering to US$2.3 Billion

#PIPE/PO

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

#PIPE/PO

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

#PIPE/PO

The Israeli pharmaceutical company's debt at the end of the first quarter of 2025 was $16.7 billion, after the company repaid $1.4 billion in debt during the quarter.

#Layoffs #FDA approval

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

#Product Stage #Layoffs

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

Teva's 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy

Why Teva Pharmaceuticals Stock Blasted 6% Higher Today

Teva's Bold $700M Gamble: Will It Be Enough to Rescue Its Plummeting Stock?

#Product Stage #Investment

Teva Pharmaceutical Industries Limited (TEVA): Among Billionaire Larry Robbins’ Stock Picks with Huge Upside Potential

TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up

#Product Stage #Partners #Customers

Why Teva Pharmaceutical Industries Limited (TEVA) Skyrocketed On Wednesday

#Customers #Partners

Teva Pharmaceutical Industries (NYSE:TEVA) Settles Class-Action Lawsuit For US$2 Million

Teva Pharmaceutical Industries Ltd (TEVA) Q1 2025 Earnings Call Highlights: Strong Growth in ...

#Product Stage #Customers

Teva Pharmaceutical Industries First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say

Teva Pharm first-quarter profit rise tops estimates

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

#Product Stage #Customers

Why Teva Pharmaceutical Stock Is Soaring Today

#Product Stage #Customers

Teva Surges On Profit Guidance Boost Despite A Mixed First-Quarter Report

FDA approves Selarsdi injection as interchangeable with Stelara

#Product Stage #Partners

Q1 2025 Corcept Therapeutics Inc Earnings Call

#Customers #Product Stage

What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q1 Earnings

Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy?

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

#Product Stage #Partners

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now

Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals

3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes

5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility

#Investment

Teva Pharmaceutical Industries (TEVA): Among the Top Healthcare Stocks to Buy According to Billionaire David Einhorn

Teva Pharmaceutical Industries (NYSE:TEVA) Pops As FDA Expands AJOVY'S Use For Pediatric Migraine Prevention

#Product Stage

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

#Product Stage #Customers #Investment

Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

#Product Stage #Partners

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

#Product Stage

Teva announces presentation of survey study on TEV-‘749

#Product Stage

Is Teva Pharmaceutical Industries (TEVA) the Most Undervalued Healthcare Stock to Buy According to Analysts?

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

#Product Stage

These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

Teva Releases Q1 2025 Aide Memoire

Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks

#Investment

Was Jim Cramer Right About Teva Pharmaceutical Industries (TEVA)?

Teva Pharmaceutical Stock Scores RS Rating Upgrade

Teva Pharmaceutical Industries (NYSE:TEVA) Sees 14% Stock Price Rise With FDA Acceptance Of New Drug Application

#Product Stage #Partners #FDA approved/pending approval

Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma

#Partners

Teva debuts global campaign encouraging people to get outside

#Customers #Management Changes

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025

#Product Stage #Customers #FDA approved/pending approval

Is Teva Pharmaceuticals Industries Limited (TEVA) the Best Weight Loss Drug Stock to Buy According to Analysts?

Teva targets schizophrenia to build on innovative medicines growth

#Product Stage #FDA approved #Partners

Is Teva Pharmaceutical Industries Limited (TEVA) the Best Low Price Pharma Stock to Invest In Right Now?

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

#Investment #Partners

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

#FDA approved/pending approval #Partners

Teva Pharmaceutical Industries Limited (TEVA): Among Bourgeon Capital’s Top Stock Picks

Richard Francis said that the question is no longer whether Teva will survive but whether it can grow more.

#Management Changes #Product Stage

Axsome secures top drug’s future with Teva patent settlement

#Partners #Customers

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

#Product Stage #Customers #FDA approved/pending approval

The Israeli pharmaceutical company's debt fell to $17.8 billion at the end of 2024, down from $19.8 billion at the end of the 2023.

#PIPE/PO

Israeli pharmaceutical giant eyes stock offering as part of its recovery plan.

#PIPE/PO

Teva Pharmaceutical Industries Full Year 2024 Earnings: EPS Misses Expectations

The company's 2025 guidance sent its share price tumbling, but analysts stress its investment in its innovative pipeline and debt reduction.

#Product Stage #Investment

Teva Pharmaceutical Industries Ltd (TEVA) Q4 2024 Earnings Call Highlights: Strong Revenue ...

#Product Stage #Partners

This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry

TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates

#Product Stage #Partners #Customers

Despite a strong 80% gain in 2024, Teva’s stock dropped after the company revealed disappointing profitability and cash flow forecasts.

#Product Stage #Management Changes #Customers

Why Teva Pharmaceuticals (TEVA) Crashed on Wednesday?

#Product Stage #Customers

Teva Stock Dives 14%. 'We're Victims Of Our Own Success,' Says CEO.

Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

#Product Stage #Partners #Customers

Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say

VF Corp, Corning, Teva: Trending stocks

Why Teva Pharmaceutical Stock Is Sinking Today

#Product Stage

Trump Media's Truth.Fi, T-Mobile, Teva: Market Minute

#Investment #Expand

The Israeli pharmaceuticals company reported strong fourth quarter results but its 2025 outlook did not meet expectations.

#Product Stage #Partners

Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript

#Product Stage #Customers #Partners #Investment

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

#Product Stage #Partners

FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis cases

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations

Update: Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks

Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook

#Customers #Partners

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

#Partners

How Teva Pharmaceuticals is thinking about Trump's return: CEO

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

#Partners

CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva

#Product Stage #Customers

Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More

#Product Stage

US analysts list Teva, Wix in 2025 top picks

#Product Stage #Partners

Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical

#Customers #FDA approved/pending approval

Sector Update: Health Care Stocks Advance Late Afternoon

IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva

#Partners

Why Teva Pharmaceuticals Industries Ltd. (TEVA) Crashed Yesterday

#Product Stage #Partners

Teva Pharmaceutical Industries Ltd (TEVA) Ends Trading Week Defying Market Bloodbath

#Partners

Why Teva Pharmaceuticals Industries (TEVA) Skyrocketed?

#Customers #Partners

Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2025

#Investment

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

#Partners

Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

My Top 10 Portfolio Holdings for 2025

#Customers #Partners

Teva price target raised to $28 from $26 at UBS

Fed decision looms, Nvidia looks to rebound: Yahoo Finance

Trending tickers: Pfizer, Micron, Nissan, Teva and National Grid

Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?

#Customers #Partners

SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study

#Partners #Investment

Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial

#Partners

Jim Cramer on Teva Pharmaceutical Industries (TEVA): A Game-Changer for Intractable Disease Treatments?

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

Teva, Cloudflare, Sanofi: Trending Tickers

Teva, Sanofi Say Inflammatory Bowel Disease Drug Study Meets Primary Endpoints

#Partners

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

#Partners

Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug

Update: Teva, Sanofi Shares Jump as Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations

#Partners

Teva Stock Soars on Early Bowel Disease Drug Data

#Partners

Teva and Sanofi jump on experimental bowel disease drug success

Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

#Partners

Teva reports positive outcomes from episodic migraine trial in young patients

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

#Acquired-by

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

TEVA Stock Down 10% in a Month: Should You Buy the Dip?

#Customers #Partners

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Teva Pharmaceutical (TEVA): The Global Leader in Affordable Medicine Under $25

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

Teva to Present at the Jefferies London Healthcare Conference

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ...

#Customers

TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase

#Customers #Partners

Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated

#Customers

Teva Pharmaceutical Flashes A Buy Signal On Upbeat Third-Quarter Report

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

Teva's Explosive Q3 Results: Pivot to Growth Strategy Shocks Investors with Record Revenue Surge

Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript

#Customers #Partners

Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say

What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?

Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock?

EC fines Teva $502m over multiple sclerosis treatment Copaxone practices

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

Teva Statement on European Commission Decision; Company to Appeal

EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug

Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns

Investors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen impressive returns of 120% over the past year

Wall Street Analysts Predict a 25.1% Upside in Teva Pharmaceutical Industries (TEVA): Here's What You Should Know

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

#Partners

Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?

Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

#Partners

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

#Partners

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva

#Partners

Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?

#Partners

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug

#Partners

Update: Teva Pharmaceutical to Pay $450 Million to Settle Anti-Kickback Allegations

Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes

Settlement with the Department of Justice addresses price hikes from $17,000 to $85,000 per year for the multiple sclerosis drug.

Teva Pharmaceuticals to Pay $450 Million to Settle Kickback Allegations

Teva to pay $450 million to resolve US kickback, price-fixing cases

Teva Pharmaceutical Industries Ltd (TEVA) Q2 2024 Earnings Call Highlights: Strong Revenue ...

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

#Customers

Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

Teva and mAbxience partner to develop biosimilar candidate for oncology

#Partners

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

#Partners

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

#Customers

Why Are Analysts Bullish On Teva Pharmaceutical Industries Limited (TEVA) Right Now?

#Customers #Investment

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

Invesco EQV European Equity Fund Bolsters Position in Teva Pharmaceutical with a 1. ...

#Investment

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

#Customers

Teva touts safety profile of once monthly schizophrenia therapy

#Customers

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)

#Customers

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

#Customers

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is favoured by institutional owners who hold 68% of the company

TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?

#Customers #Partners

Teva to Present at the Bank of America 2024 Global Healthcare Conference

#Management Changes

Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial

#Customers

Teva agrees to pay Baltimore City $80m for fuelling opioid epidemic

#Customers

Update: Teva Pharmaceutical Faces Fine in EU for Dismissive Tactics Against Rivals

Sector Update: Health Care Stocks Advance Late Afternoon

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability

#Investment

Teva Named One of the World's Most Sustainable Companies

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

#Management Changes

Teva Pharmaceutical Industries Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.

#Customers, Management Changes

TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up

#Customers #Partners #Expand

Teva Pharmaceutical Industries (TEVA) Q2 2024 Earnings Call Transcript

#Customers #Investment #Expand

Teva Pharmaceutical Industries (TEVA) Reports Q2 Earnings: What Key Metrics Have to Say

#Customers

Is Teva Pharmaceutical Industries (TEVA) Stock Undervalued Right Now?

#Investment

Teva Pharma Flirts With Breakout As Generic Drugs Drive Beat-And-Raise

#Customers

Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance

#Customers #Expand

Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings

#Customers #Acquisition

Unveiling Teva Pharmaceutical Industries (TEVA) Q2 Outlook: Wall Street Estimates for Key Metrics

#Investment

Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Teva reports positive data from Phase III paediatric migraine prevention trial

#Investment #Expand

TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids

#Customers #Expand

Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine

3 No-Brainer Stocks to Buy With $200 Right Now

#Investment

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

#Customers, Partners, Management Changes

FTC investigates Teva over contested product patents

#Customers

Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024

Correction: Top Midday Stories: Boeing to Acquire Spirit AeroSystems; Robinhood Acquires Pluto; FTC Probes Teva; BlackRock Acquires Preqin; SCOTUS Grants Trump Some Immunity

#Acquisition

Update: Market Chatter: Teva Pharmaceuticals Faces FTC Probe on Patent Listings

#Customers

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020

Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States

Here's Why You Should Consider Buying Alvotech (ALVO) Stock

#Partners #Expand

Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a Positive Rating from Analysts?

#Investment #Customers

טבע מפטרת עשרות עובדים בישראל — ומעבירה משרות לחו"ל

#Layoffs #Expand

7 A-Rated Biotech Stocks Worth Betting on in June

#Investment

Teva sues Corcept over mifepristone 'monopoly' for rare disorder

#Customers #Partners

TEVA Stock Rises 135% in a Year: What's Driving the Recovery?

#Customers #Partners #Management Changes

Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)

FDA approves Teva Pharmaceuticals’ AUSTEDO XR for TD and HD chorea

#Customers, Partners

Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)

טבע משקיעה 10 מיליון דולר בטכנולוגיה רפואית ישראלית

#Investment, Partners

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

#Partners #Expand

Insider Sale: Chief Accounting Officer Amir Weiss Sells 28,135 Shares of Teva Pharmaceutical ...

#Public Trading

Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade

#Customers, Partners

Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?

#Investment

Israel’s Once-Dominant Drugmaker Is Revived by Innovation

#Investment

Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2024 Earnings Call Transcript

#Management Changes #Investment

Affirm stock sinking, Good Buy or Goodbye: Market Domination

#Customers, Partners, Management Changes

Teva and Medincell report positive data for TEV-‘749 in schizophrenia trial

#Partners

TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up

#Partners #Customers

Teva Pharmaceutical Industries First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

#Customers

Teva Pharmaceutical Industries (TEVA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

#Customers

Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First Quarter

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

UPDATE 1-Teva Pharm Q1 profit misses estimates, revenue risea

#Customers

Teva Pharmaceutical Industries (TEVA) Q1 2024 Earnings Call Transcript

#Investment #Management Changes #Expand

Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook

Teva Pharm Q1 profit misses estimates, revenue risea

#Customers, Partners

Teva Earnings Are Soon. What Could Keep the Stock Gains Going.

20 States with the Highest Fertility Rates in the US

#Customers, Partners, Expand

Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?

#Customers, Investment

Teva Pharmaceutical Industries (NYSE:TEVA) shareholders have earned a 54% return over the last year

#Investment

Unlocking Q1 Potential of Teva Pharmaceutical Industries (TEVA): Exploring Wall Street Estimates for Key Metrics

#Investment

A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation

#None

Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets

Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...

#Customers #Investment

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript

#Customers #Partners #Management Changes #Expand

Teva to Present at the 2024 Bank of America Healthcare Conference

Q1 2024 Corcept Therapeutics Inc Earnings Call

#Customers #Investment #Management Changes

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

#Partners #Expand

UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents

#Customers #Partners

11 Best Low Price Pharma Stocks To Invest In

#Investment, Acquisition

Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris

#Customers, Expand

3 Generic Drug Stocks to Watch Amid Challenging Market Prospects

#Customers, Expand

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets

Israeli economy has proven to thrive despite crisis: Expert

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

3 No-Brainer Stocks to Buy With $600 Right Now

#Investment, Acquisition

Biden and Senator Sanders to highlight efforts lower cost of asthma inhalers

#Customers

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement

UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent

#Customers

Teva, Viatris win new chance to challenge J&J schizophrenia drug patent

#Customers

Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?

#Expand

Institutional investors have a lot riding on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with 67% ownership

#Investment

Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?

#Customers #Partners #Management Changes

25 Countries with the Lowest Fertility Rates

#Customers, Investment

Q4 2023 Alvotech SA Earnings Call

#Customers #Partners #Expand

GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US

#Customers

AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US

#Customers

Now That Two Inhaler Makers Are Capping Patient Costs, Will More Follow?

#Customers

EVP, CFO Eliyahu Kalif Sells 77,550 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

#Management Changes

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

#Partners #Expand

UPDATE 2-Teva Pharm to stay as unified drugmaker, sees big interest in API business, says CEO

#Partners #Acquisition

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting

Q4 2023 Corcept Therapeutics Inc Earnings Call

#Customers #Investment #Expand

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Call Transcript

#Customers #Management Changes

Teva enlarges workforce for first time since 2016

#Expand

Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight

#Customers #Partners #Management Changes #Expand

Teva Pharmaceutical upgraded at Piper Sandler

#Investment

David Abrams Adjusts Portfolio, Meta Platforms Sees Notable Reduction

#Investment

Chief Accounting Officer Amir Weiss Sells 31,766 Shares of Teva Pharmaceutical Industries Ltd

#Management Changes

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Just Reported And Analysts Have Been Lifting Their Price Targets

#Investment

TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up

#Customers #Partners #Management Changes

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q4 2023 Earnings Call Transcript

#Investment #Management Changes #Expand

Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript

#Management Changes, Investment

Teva Plans to Divest Drug Ingredients Business in Next Step of Strategic Shift

Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy

Teva Reports Growth in Fourth Quarter and Full Year 2023

Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

#Customers

UPDATE 2-Teva to divest active pharmaceutical ingredient business

#Customers #Management Changes

How Teva's CEO is implementing his 'pivot to growth' strategy

#Management Changes #Acquisition

UPDATE 1-Teva Pharm sees lower 2024 profit after large Q4 beat

#Partners #Management Changes

Teva to divest active pharmaceutical ingredient business

#Investment

Teva, GSK Put Up Bullish Fourth-Quarter Performances. Here's Where Novartis Fell Short.

Teva Pharma sees lower 2024 profit but higher sales after large Q4 beat

#Partners #Expand

Teva Pharmaceutical Industries Ltd (TEVA) Reports Solid Growth in 2023 Earnings

#Customers #Investment

Teva to sell API activity, beats analysts on Q4

#Management Changes

50 Most Populated Countries in the World in 2024

#Customers, Partners

Teva to spin out API business in pursuit of future growth

#Management Changes

Teva ends 2023 as Israeli co with biggest profit on Wall Street

#Management Changes

Teva buys rights for Israeli co Biolojic's asthma treatment

#Partners, Investment

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

TEVA PHARMACEUTICALS REPORTS STRONG Q3 2023 RESULTS RAISES REVENUE FORECAST

#Customers #Expand

13 Most Undervalued Pharma Stocks To Buy According To Analysts

#Investment

Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program

Israeli drugmaker Teva loses appeal against EU fine -EU court ruling

#Customers

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

UPDATE 1-Drugmaker Teva does not see big impact on business from Israel-Hamas war

#Customers #Partners

Health Care Roundup: Market Talk

Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023

Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment

Sanofi (SNY) Signs Deal to Co-Develop Teva's IBD Candidate

#Partners #Investment

Teva Leans Into Sanofi's 'Pipeline-In-A-Product' Expertise In $1.5 Billion Deal

Teva teams with Sanofi on inflammatory bowel treatment

#Partners #Investment

Teva Announces Changes to Executive Management Team

US judge overturns Eli Lilly's $176.5 million loss in Teva patent case

#Customers

Unveiling Teva Pharmaceutical Industries (TEVA)'s Value: Is It Really Priced Right? A ...

#Public Trading

3 No-Brainer Stocks to Buy With $20 Right Now

Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference

Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023

With 55% ownership of the shares, Teva Pharmaceutical Industries Limited (NYSE:TEVA) is heavily dominated by institutional owners

#Investment

Q2 2023 Alvotech SA Earnings Call

#Partners #Investment

Alkermes (ALKS) Grants Teva License to Market Generic Drug

#Partners

TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)

#Investment #Customers

Teva Pharma: generics titan attempts to put the stopper in legal problems

TEVA to Pay $250 Million to Settle Price-Fixing Charges

#Investment #Customers

Teva Settles Price Fixing Charges With U.S. DOJ

UPDATE 2-Teva to pay $225 mln, divest cholesterol drug to settle price-fixing charges

#Investment

Teva to pay $225 million, divest cholesterol drug to settle price-fixing charges

#Management Changes

Teva Agrees to Pay $225 Million to Settle U.S. Price-Fixing Charges

Teva to pay $225M to settle cholesterol drug price-fixing charges

#Customers #Investment

Q2 2023 Societal CDMO Inc Earnings Call

#Customers #Partners

Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical

#Customers, Partners, Acquisition

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

#Customers, Partners, Acquisition

Teva agrees to pay $126 million to US hospitals over opioids

#Customers #Investment

Teva agrees to pay $126 mln to US hospitals over opioids

#Customers #Investment

TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up

#Customers #Management Changes

Teva stock pops on Q2 results, CEO sees 'significant' potential for trio of branded drugs

#Customers #Management Changes #Layoffs #Expand

Teva Retakes Its 200-Day Line After Second-Quarter Beat And Raise

Huntington's treatment helps Teva beat profit estimates as CEO eyes newer drug opportunities

#Customers #Management Changes

UPDATE 1-Teva CEO says not too late to launch Humira biosimilar in 2024

#Customers #Partners

Teva Pharmaceutical Industries (TEVA) Q2 2023 Earnings Call Transcript

Teva Reports Second Quarter 2023 Financial Results

Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries Ltd. (TEVA) Q2 Earnings

#Customers

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development

Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership

Exelixis deal sets generic version of cancer drug for release in 2031

Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine

Patients Can’t Get Some Lifesaving Drugs. What’s Causing the Shortages.

11 Best Medical Stocks Under $10

#Investment

3 Bargain Stocks to Buy on the Dip

#Investment

Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients

Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims

Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

Pharmaceutical Giants Set $19 Billion Opioid Settlement as States Debate How to Spend It

Is AbbVie or Amgen the Better Bargain Buy Right Now?

Teva Concludes Nationwide Opioids Settlement Agreement

Teva to pay Nevada $193 million over role in opioid epidemic

#Customers #Investment

Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management

Teva Pharmaceuticals Just Made a Big Announcement, but Is It a Buy?

#Investment #Expand

Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023

Shareholders in Teva Pharmaceutical Industries (NYSE:TEVA) have lost 66%, as stock drops 6.3% this past week

#Customers

Analysts are Upgrading These 10 Stocks

#Investment

Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical

#Customers #Partners #Acquisition

3 Generic Drug Stocks to Watch Amid Macro Headwinds

#Customers, Partners, Acquisition

15 Stocks Warren Buffett Sold

#Investment, Management Changes

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting

Teva Pharm CEO sees $2.5 bln in revenue for Austedo drug by 2027

#Customers #Expand

UPDATE 1-Teva Pharm CEO sees $2.5 bln in revenue for Austedo drug by 2027

#Investment #Expand

Why Teva Pharmaceutical Stock Is Jumping Today

Teva Launches New "Pivot to Growth" Strategy

Teva targets growth through innovation

#Management Changes #Expand

Teva to Slim Down Generic Drug Business in Turnaround Effort. The Stock Is Jumping.

Teva profit plummets, stock slides | CTech

#Customers #Management Changes

גלובס זירת העסקים של ישראל

#Acquisition #Layoffs #Management Changes

Teva names Richard Francis as new CEO after Kåre Schultz departure | CTech

#Management Changes

Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities - Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFC

Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes

Teva Post Lupin Deal To Launch Austedo Generic Rival In 2033

#Partners

Teva agrees opioid settlement with Rhode Island

#Customers

Teva announces debt recycling measures

#Investment #Layoffs

Teva and Tikun Olam-Cannbit sign medical cannabis deal

#Partners #Expand

Teva wins opioids case in California court

#Customers

Teva to lay off 200 in Israel

#Layoffs

Teva readying to distribute Covid-19 vaccine in Israel

#Partners

Teva Announces New Analysis of Consistency in Migraine Days Over the Course of a Dosing Regimen for AJOVY® (fremanezumab-vfrm) Injection Published in Headache

https://www.marketwatch.com/press-release/teva-launches-two-digital-inhalers-in-the-us-airduo-digihaler-fluticasone-propionate-and-salmeterol-inhalation-powder-and-armonair-digihaler-fluticasone-propionate-inhalation-powder-2020-09-21?siteid=bigcharts&dist=bigcharts&tesla=yer%C2%AE-fluticasone-propionate-Inhalation-Powder

Teva is recruiting Israeli academia to help produce its next breakthrough drug

#Partners, Investment

Teva announces 350 layoffs at Negev plant

#Layoffs

Teva joins forces with Icelandic firm to gain edge on biosimilars

Teva scales down Japanese operations

#Partners #Management Changes

Teva Announces Availability of ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder for Patients with Asthma and COPD BioSpace

Teva's Austedo wins marketing approval for China

#Customers #Expand

Teva launches Rituxan biosimilar for Rheumatoid Arthritis

#Partners #Customers

Teva launches auto-injectable Ajovy in US

#Customers, Expand

Teva Israel CEO quits to head medical cannabis co Cannbit

#Management Changes #Acquisition

US court upholds validity of Teva's Ajovy patents

#Customers

Teva drugs approved for emergency Covid-19 trials

#Customers #Expand

https://www.jpost.com/HEALTH-SCIENCE/Teva-donates-potential-coronavirus-treatment-to-hospitals-across-the-US-621688

#Customers, Expand

Teva asks FDA to define Copaxone as biologics drug

#Investment

Teva digital asthma inhaler wins FDA nod

#Customers

Teva CEO: We have to launch new products

#Customers #Management Changes #Layoffs #Investment

Teva Israel to Stop Distribution of Weight Loss Drug Amid Cancer Concerns

#Customers, Partners

Teva Receives FDA Approval for Migraine Autoinjector

#Customers #Partners

Teva must return non-MS Copaxone rights to Proneuron

#Partners

Teva looks to China

#Management Changes #Layoffs #Investment

Teva seeks blockbuster drug to succeed Copaxone

#Partners, Investment

Teva to pay $54m to settle Copaxone bribery case in US

#Customers

Teva teams with Weizmann Institute, Tel Aviv U

#Partners

Teva's Israeli Plant Receives FDA Stamp of Approval for Migraine Drug Manufacturing

#Expand

Teva Announces $23.25 Billion Opioid Abuse Settlement Agreement

#Customers, Investment

Teva Makes $15 Billion Settlement Offer in U.S. Opioid Case, Report Says

#Acquisition #Investment

Teva EVP global operations steps down

#Management Changes

Teva enters Israel's cannabis market

#Partners

Teva to merge communications into HR

#Management Changes

Teva Announces CFO Leadership Transition

Teva to sell Oncotest to Rhenium

#Acquisition #Management Changes

Teva to Pay California $69 Million in Narcolepsy Drug Settlement

#Investment

Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder BioSpace

Teva Completes Facilities Purchase in Pennsylvania for North America Research & Development Campus

Teva announces launch of a generic version of Tracleer® in US

Teva Reaches $85 Million Settlement in Oklahoma Opioid Damages Suit

https://www.jpost.com/Israel-News/Teva-rejects-wrongdoing-in-drug-price-fixing-lawsuit-589455

#Customers #Layoffs

Teva CEO unsure about 2020 growth

#Management Changes

Teva Completes $47.5 Million Sale of Northern Israeli Plant to Private Equity Fund FIMI

#Acquisition

Teva abandons fremanezumab cluster headache trial

#Management Changes

Teva launches generic overactive bladder treatment

#Customers, Expand

FDA approves Teva opioid antidote nasal spray

#Customers

Teva rebrands to raise consumer awareness

#Customers, Expand

Teva migraine drug Ajovy wins European approval

#Customers #Acquisition

Teva Makes Headway in European Copaxone Patent Case

#Customers

Teva launches generic iron overload treatment

#Customers

Teva reconnecting to Israel's startup ecosystem

#Partners #Management Changes

FIMI buys Teva plant in Kiryat Shmona

#Acquisition #Management Changes

Morgan Stanley upgrades Teva

#Investment

http://www.marketwatch.com/story/teva-reinforces-leadership-position-in-respiratory-with-acquisition-of-gecko-health-innovations-2015-09-25

Teva in crisis: Group of investors may offer to buy part of Teva's Israel operations

#Layoffs #Acquisition

Teva buys Mexican co Rimsa for $2.3b

#Acquisition, Expand

Buffett buys $358 million stake in Teva

Teva loses $235m patent trial to GSK

#Customers

Teva buys rights to chronic pain drug for $250m

#Partners, Investment

Teva completes acquisition of Actavis Generics

#Acquisition #Investment

http://www.tevapharm.com/news/teva_to_acquire_allergan_generics_for_40_5_billion_creating_a_transformative_generics_and_specialty_company_well_positioned_to_win_in_global_healthcare_07_15.aspx

Teva: 35% of senior management are women

#Customers, Management Changes

Teva launches generic contraceptive pill

#Customers

Teva invests $30m in US co Wave Life Sciences

#Investment, Acquisition, Partners

Teva acquires Gecko Health Innovations

#Acquisition

Teva buys 51% stake in US co Immuneering for $60m

#Acquisition #Investment

Teva buying Allergan Generics for $40.5b

#Acquisition

Teva completes acquisition of 4.6% Mylan stake

#Acquisition

Teva launches generic osteoporosis drug

#Customers, Expand

Teva to acquire Auspex for $3.2b

#Acquisition

Teva close to major acquisition - report

#Acquisition

Teva raises extra $658m in underwriters' options

#Investment #Acquisition

Similar Companies

Driven by Finder AI

Primary sector

Total funding

Undisclosed

Funding stage

undefined

Number of employees

Founded

1/1901

Team Members

undefined

Contact Team

Affiliated Organizations

(undefined)

Locations

Israel

Photos & videos

(0)

No Data, yet.

Sorry, no content found under this section.

Teva Pharmaceuticals Business

Business models

Product stage

Geographic markets

Products

Sector

Primary:

Target Customer

Core Technology

Teva Pharmaceuticals Financials

Total funding Undisclosed

Market cap Undisclosed

Last funding Undisclosed

Funding stage undefined

Total rounds undefined

Investors undefined

Cumulative Funding Raised Over Time ($)

Public Offerings & Exits

Public Offering

Undisclosed

Jan 1982

Stock Exchange

NYSE

Valuation Undisclosed

Undisclosed

Initial Public Offering EXIT

Undisclosed

Jan 1951

Stock Exchange

TASE

Valuation Undisclosed

Undisclosed

Private Equity Funding

PIPE

$400M

Mar 2026

1 Investors

$400M

PIPE

$150M

Apr 2024

1 Investors

$150M

PIPE

$358M

Feb 2018

3 Investors

$358M

Mergers and Acquisitions

M&A

$900M

Apr 2026

Type Acquisition

Acquired

Emalex Biosciences

$900M

M&A

Undisclosed

Oct 2016

Type Acquisition

Acquired

Anda

Undisclosed

M&A

$40B

Aug 2016

Type Acquisition

Acquired

Actavis

$40B

M&A

$2.3B

Oct 2015

Type Acquisition

Acquired

Rimsa

$2.3B

M&A

Undisclosed

Sep 2015

Type Acquisition

Acquired

Gecko Health Innovations

Undisclosed

M&A

$3.5B

Mar 2015

Type Acquisition

Acquired

Auspex Pharmaceuticals

$3.5B

M&A

$825M

Jun 2014

Type Acquisition

Acquired

Labrys Biologics

$825M

M&A

$144M

Jan 2014

Type Acquisition

Acquired

NuPathe

$144M

M&A

$165M

Jun 2013

Type Acquisition

Acquired

MicroDose Therapeutx

$165M

M&A

$6.8B

May 2011

Type Acquisition

Acquired

Cephalon

$6.8B

M&A

$7.46B

Jul 2008

Type Acquisition

Acquired

Barr Pharmaceuticals

$7.46B

M&A

$220M

Aug 1999

Type Acquisition

Acquired

Copley Pharmaceutical

$220M

News Over Time

News Articles